Phase 2, Randomized, Double-Blind, Placebo Controlled, Dose-Finding Study to Assess the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Vadadustat in Japanese Subjects With Anemia Secondary to Non-Dialysis Dependent Chronic Kidney Disease (NDD-CKD)
The trial evaluated vadadustat, a hypoxia-inducible factor stabilizer, for treating anemia in Japanese patients with NDD-CKD. The study was randomized, double-blind, and placebo-controlled, involving 51 participants across multiple sites in Japan. The primary endpoint was the change in hemoglobin levels over 6 weeks.
Indication: Anemia
Modality: small molecule
Target: Anemia secondary to Non-Dialysis Dependent Chronic Kidney Disease (NDD-CKD)
Sponsor: Akebia Therapeutics
Source URL: ClinicalTrials.gov
Source updated: Apr 08, 2021
Ingested: May 30, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by target_normalized: Anemia secondary to Non-Dialysis Dependent Chronic Kidney Disease (NDD-CKD)
View original source fields
Condition raw: Anemia
Condition normalized: Anemia
Modality raw: Anemia
Modality normalized: small molecule
Target raw: Anemia secondary to Non-Dialysis Dependent Chronic Kidney Disease (NDD-CKD)
Target normalized: Anemia secondary to Non-Dialysis Dependent Chronic Kidney Disease (NDD-CKD)